Sareum
Holdings PLC
("Sareum"
or the "Company")
Award of
Share Options
Transfer
of Shares
Exercise
of Warrants
Issue of
Adviser Fee Shares
Cambridge, UK,
16 December 2024 - Sareum Holdings plc (AIM:
SAR), a biotechnology company developing next generation kinase
inhibitors for autoimmune disease and cancer, announces the grant of options to Tim Mitchell
(Chief Operating Officer), John Reader (Founder and Chief
Scientific Officer) and Stephen Parker (Executive Chairman)
over, in aggregate, 4,400,000 ordinary shares of 1.25 pence each in the capital of the
Company ("Ordinary Shares")
(the "Options"). A total of
890,000 Options will be granted under the Company's Enterprise
Management Incentive ("EMI") plan, and the remaining Options
will be granted under an unapproved share option scheme on
identical terms to the EMI options, as further detailed
below.
The Options have an exercise price of 30.48
pence, being equal to a premium of 15.0% to the closing mid-market
price of an Ordinary Share on 13 December 2024, being the last
trading day before the award of the Options. The Options will be
structured to vest from 16 December 2027 and will lapse on the
fifth anniversary of the date of grant. Details of the individual
tranches are as follow:
·
Tranche 1: 50% of the Options will vest on 16 December
2027
·
Tranche 2: 50% of the Options will vest on 16 December 2027
providing the Company has met certain commercial and technical
milestones
Details of the Options award is detailed in the
table below:
|
Director / PDMR
|
Current options
held
|
New EMI options
awarded
|
New unapproved options
awarded
|
Total options
held
|
|
Tim Mitchell, Founder &
COO
|
1,211,434
|
445,000
|
755,000
|
2,411,434
|
|
John Reader, Founder &
CSO
|
1,211,434
|
445,000
|
1,555,000
|
3,211,434
|
|
Stephen Parker, Executive
Chairman
|
492,908
|
-
|
1,200,000
|
1,692,908
|
Following the grant of the new Options, a total
of 7,430,058 options are outstanding, representing approximately
6.0% of the Company's issued share capital following
Admission.
Transfer of
Shares
The Company also announces that Dr. Tim
Mitchell, has transferred 451,960 of his Ordinary Shares to his
spouse, resulting in both Dr Mitchell and his spouse holding
651,960 Ordinary Shares, representing, in aggregate, approximately
1.04% of the Company's issued share capital following
Admission.
Exercise of
Warrants
The Company announces that it has received an
exercise of warrants notice to subscribe for a total of 159,091 new
Ordinary Shares at a price of 22.5 pence per new Ordinary Share for
a total consideration to the Company of £35,795.48.
Issue of
Adviser Fee Shares
Finally, the Company announces that it has
issued 22,222 Ordinary Shares to an adviser to settle amounts due
in relation to advice provided.
Admission and Total Voting Rights
The Company has applied for 181,313
new Ordinary Shares to be to be admitted to trading on AIM
("Admission") by 8.00 a.m.
on or around 20 December 2024.
The new Ordinary Shares will, when
issued, be credited as fully paid and will rank pari passu in all respects with the
existing Ordinary Shares of the Company including the right to
receive all dividends or other distributions made, paid or declared
in respect of such shares after Admission.
Following Admission, the total
number of Ordinary Shares in issue will be 124,927,651 and the
total number of voting rights will thereafter be 124,927,651 and
this figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
share capital of the Company under the FCA's Disclosure Guidance
and Transparency Rules.
For further
information, please contact:
|
Sareum Holdings plc
Stephen Parker, Executive
Chairman
|
01223 497700
ir@sareum.co.uk
|
|
Strand Hanson Limited (Nominated
Adviser)
James Dance / James
Bellman
|
020 7409 3494
|
|
Hybridan LLP (Corporate
Broker)
Claire Noyce
|
020 3764 2341
|
|
ICR Healthcare (Financial PR)
Jessica Hodgson / Davide Salvi /
Kumail Waljee
|
020 3709 5700
|
About
Sareum
Sareum (AIM: SAR) is a
biotechnology company developing next generation
kinase inhibitors for autoimmune disease and cancer.
The Company is focused on developing
next generation small molecules which modify the activity of the
JAK kinase family and have best-in-class potential. Its lead
candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1.
SDC-1801 is a potential treatment for a range of
autoimmune diseases, including psoriasis, and has completed Phase 1
clinical development.
Sareum is also developing SDC-1802,
a TYK2/JAK1 inhibitor with a potential application for cancer
immunotherapy.
Sareum Holdings plc is based in
Cambridge, UK, and is quoted on the AIM market of the London Stock
Exchange, trading under the ticker SAR. For further information,
please visit the Company's website at www.sareum.com.
PDMR
Notification Form:
The below form is disclosed in accordance with
the requirements of the EU's Market Abuse Regulation and in
relation to certain dealings by directors pursuant to the Director
Subscription and issue of Salary Conversion Shares:
1.
|
Details of the person discharging
managerial responsibilities/person closely associated
|
a)
|
Name:
|
Tim Mitchell
|
2.
|
Reason for the
notification
|
a)
|
Position/status:
|
PDMR - Founder & COO
|
b)
|
Initial
notification/Amendment:
|
Initial notification
|
3.
|
Details of the issuer, emission
allowance market participant, auction platform, auctioneer or
auction monitor
|
a)
|
Name:
|
Sareum Holdings plc
|
b)
|
LEI:
|
213800PKERN2DY8FFM72
|
4.
|
Details of the transaction(s):
section to be repeated for (i) each type of instrument; (ii) each
type of transaction; (iii) each date; and (iv) each place where
transactions have been conducted
|
a)
|
Description of the financial
instrument, type of instrument:
Identification code:
|
Options over ordinary shares of 0.0125 pence
each in the share capital of Sareum Holdings plc
GB00B02RFS12
|
b)
|
Nature of the
transaction:
|
Issue of options
|
c)
|
Price(s) and volume(s):
|
|
Price(s)
|
Volume(s)
|
|
30.48p
|
1,200,000
|
|
d)
|
Aggregated information:
· Aggregated
volume:
· Price:
|
Single transaction as in 4c) above
|
e)
|
Date of the transaction:
|
16 December 2024
|
f)
|
Place of the transaction:
|
Outside a trading venue
|
1.
|
Details of the person discharging
managerial responsibilities/person closely associated
|
a)
|
Name:
|
John Reader
|
2.
|
Reason for the
notification
|
a)
|
Position/status:
|
Director - Founder &
CSO
|
b)
|
Initial
notification/Amendment:
|
Initial notification
|
3.
|
Details of the issuer, emission
allowance market participant, auction platform, auctioneer or
auction monitor
|
a)
|
Name:
|
Sareum Holdings plc
|
b)
|
LEI:
|
213800PKERN2DY8FFM72
|
4.
|
Details of the transaction(s):
section to be repeated for (i) each type of instrument; (ii) each
type of transaction; (iii) each date; and (iv) each place where
transactions have been conducted
|
a)
|
Description of the financial
instrument, type of instrument:
Identification code:
|
Options over ordinary shares of 0.0125 pence
each in the share capital of Sareum Holdings plc
GB00B02RFS12
|
b)
|
Nature of the
transaction:
|
Issue of options
|
c)
|
Price(s) and volume(s):
|
|
Price(s)
|
Volume(s)
|
|
30.48p
|
2,000,000
|
|
d)
|
Aggregated information:
· Aggregated
volume:
· Price:
|
Single transaction as in 4c) above
|
e)
|
Date of the transaction:
|
16 December 2024
|
f)
|
Place of the transaction:
|
Outside a trading venue
|
1.
|
Details of the person discharging
managerial responsibilities/person closely associated
|
a)
|
Name:
|
Stephen Parker
|
2.
|
Reason for the
notification
|
a)
|
Position/status:
|
Director - Executive
Chairman
|
b)
|
Initial
notification/Amendment:
|
Initial notification
|
3.
|
Details of the issuer, emission
allowance market participant, auction platform, auctioneer or
auction monitor
|
a)
|
Name:
|
Sareum Holdings plc
|
b)
|
LEI:
|
213800PKERN2DY8FFM72
|
4.
|
Details of the transaction(s):
section to be repeated for (i) each type of instrument; (ii) each
type of transaction; (iii) each date; and (iv) each place where
transactions have been conducted
|
a)
|
Description of the financial
instrument, type of instrument:
Identification code:
|
Options over ordinary shares of 0.0125 pence
each in the share capital of Sareum Holdings plc
GB00B02RFS12
|
b)
|
Nature of the
transaction:
|
Issue of options
|
c)
|
Price(s) and volume(s):
|
|
Price(s)
|
Volume(s)
|
|
30.48p
|
1,200,000
|
|
d)
|
Aggregated information:
· Aggregated
volume:
· Price:
|
Single transaction as in 4c) above
|
e)
|
Date of the transaction:
|
16 December 2024
|
f)
|
Place of the transaction:
|
Outside a trading venue
|
END